Discuss PSX Sector - Pharmaceuticals

  • ALERT! Investment Disclaimer
    All the information on FORUMS.COM.PK / Finance.PK is provided for information purpose only. The information has been obtained from the sources believed to be reliable. Analysis provided is opinion only. BUY / HOLD / SELL call may be True / False / or Misleading. You are solely responsible for all types of investment and trading decisions made by you.
  • جو شخص بہانہ بنانے میں بہت اچھا ہو ، وہ کسی اور کام میں اچھا نہیں ہو سکتا
  • پیسہ بدترین آقا ہے، مگر بہترین غلام بھی ہے
  • کسی فرد یا قوم کو برباد کرنا ہے تو اس کی امید کو مار ڈالیے اور اگر اسے تعمیر کرنا ہے اس کی امید کا دیا روشن کیجئے
  • کامیابی سوچ سے ملتی ہے
  • زندگی کی دوڑ میں دوسروں سے آگے نکلنے کیلئے تیز چلنا ضروری نہیں، بلکہ ہر رکاوٹ کے باوجود چلتے رہنا اور مسلسل چلتے رہنا ضروری ہے
  • جب باتیں آمنے سامنے ہوتی ہیں تو جھوٹ اور غلط فہممی کا خاتمہ ہو جاتا ھے
  • بہت اونچے پہاڑ پر چڑھنے کے لئیے قدم آہستہ آہستہ اٹھانا پڑتے ہیں
  • تین چیزیں نیکی کی بنیاد ہیں، تواضع بے توقع, سخاوت بے منت اور خدمت بے طلبِ مکافات
  • غربت اور افلاس کی وجہ پیداوار کی کمی نہیں، بلکہ اسکی غلط تقسیم ہے
  • دولت ہونے سے آدمی اپنے آپ کو بھول جاتا ہے اور دولت نہ ہونے سے لوگ اس کو بھول جاتے ہیں

xResearch

Active member
Apr 9, 2017
1,918
1
38
#2
JS Research
Federal Budget Review FY18


Pharmaceutical - Positive: The limit for expenditure incurred by pharmaceutical companies on sales promotion, advertisement and publicity is being enhanced from 5% to 10% of turnover.
 

xResearch

Active member
Apr 9, 2017
1,918
1
38
#3
Alfalah Securities
Federal Budget Review FY18


Health/Pharma

  • Customs Duty on the import of Pre-fabricated Modular Clean Rooms (used in Pharma, bio tech. and life sciences) is proposed to be reduced from 20% to 3%.
  • Fabric, (non-woven) is used in the manufacturing of bandages, surgical gowns, wound dressings etc. To provide relief to the pharmaceutical sector and reduce cost for patients, customs duty to be reduced from 16% to 5%.
  • Machinery, equipment, apparatus, appliances, wheelchairs, medical, surgical, dental furniture and spares etc. import are allowed duty free by charitable non-profit institutions, now the scope of this exemption is being expanded by including Hospitals of Armed Forces, Fauji Foundation, and Pakistan Atomic Energy Commission.
  • Electric Cigarettes customs duty increased from 3% to 20% owing to its harmful effects.
 

xResearch

Active member
Apr 9, 2017
1,918
1
38
#4
Summit Capital Research
Federal Budget Review FY18



Pharmaceutical

  • Enhancement of admissible sales promotion and advertising expenses raised from 5% to 10% of turnover. Positive
 

xResearch

Active member
Apr 9, 2017
1,918
1
38
#5
AHL Research
06 October 2017


Pharmaceuticals
1HCY17 Pharmaceutical Profitability up by 36% YoY, ex-FEROZ


Profitability surged by 11% YoY
In 1HCY17, domestic pharmaceutical sector accumulated recorded profit of PKR 4,922mn, up by 11% YoY (Ex-Feroz up by 36% YoY). Our sample includes five companies (ABOT, SEARL, GLAXO, SAPL and FEROZ) which have 90% weight in the sector’s market capitalization.

SAPL Recorded Highest Growth in Profitability
Highest growth in profitability was achieved by Sanofi-Aventis (+153%) on the back of robust growth in vaccine business. GLAXO’s earnings surged by 56% YoY as it benefited from its presence in consumer health care and participation in tenders of Punjab Government. The profitability of SEARL grew by 22% YoY on the back of higher sales and lower effective taxation (PBT was up by 2% YoY). Whereas ABOT’s bottom-line grew moderately by 13% YoY due to inability to pass on the full inflationary impact.

FEROZ decays the profitability
Meanwhile profitability of Pharma sector (ex-FEROZ) grew by 36% YoY to reach PKR 4,902mn. Ferozsons PAT declined by 98% YoY attributable to plunge in net revenues. The declining drug ‘SOVALDI’ (highest selling drug of FEROZ) was substituted by several cheaper generic brands of Sofsobuvir available in the market which eroded the company’s top-line by 52%, hence profitability tanked.

Margins Remained Flat
The pharmaceutical sector has managed to maintain its gross margins at 34% during 1HCY17. On a YoY basis, SEARL conserved its margins at 39% whereas SAPL and GLAXO’s margins surged by 3% and 1% to 37% and 27%, respectively. However, ABOT and FEROZ’s margins compressed to 38% YoY (down by 1%) and 32% YoY (down by 8%); particularly due to inflationary pressures and lackluster revenues, respectively. Pertinently, Drug Pricing Committee (DPC) announced expected increase in drug prices by 3%, which would bode well for the Pharma sector profitability.
 

Forum statistics

Threads
979
Messages
4,562
Members
137
Latest member
_Snooker2.0

Latest posts